Laboratory of Experimental Hematology and Cell Immunotherapy, Department of Clinical Hematology, University Hospital, Brno, Czech Republic.
Med Oncol. 2006;23(3):377-84. doi: 10.1385/MO:23:3:377.
Adoptive immunotherapy is a promising approach in the treatment of multiple myeloma. We have tested the identification, separation, and expansion of allogeneic myeloma-specific T cells in vitro. Irradiated myeloma cell line ARH 77 has been used to stimulate allogeneic CD4(+) and CD8(+) T lymphocytes. Activated myeloma-specific T cells that produced interferon-gamma were isolated using immunomagnetic beads and further expanded in vitro to numbers of up to 400 x 106 T cells. Specificity of the T lymphocytes was tested using a 5-(6-)carboxyfluoresceine diacetate succinimidyl ester (CFSE)-based cytotoxicity test. This study demonstrates the feasibility of identification and isolation of tumor-specific T cells from allogeneic donors that can be expanded in vitro to numbers useful for clinical applications.
过继免疫疗法是多发性骨髓瘤治疗中很有前途的方法。我们已经测试了同种异体骨髓瘤特异性 T 细胞的体外鉴定、分离和扩增。用辐照骨髓瘤细胞系 ARH 77 来刺激同种异体 CD4(+)和 CD8(+)T 淋巴细胞。利用免疫磁珠分离产生干扰素-γ的骨髓瘤特异性 T 细胞,并在体外进一步扩增至高达 400×106 T 细胞。使用基于 5-(6-)羧基荧光素二乙酸琥珀酰亚胺酯 (CFSE)的细胞毒性试验测试 T 淋巴细胞的特异性。这项研究证明了从同种异体供体中鉴定和分离肿瘤特异性 T 细胞并在体外扩增到可用于临床应用的数量的可行性。